Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.

Papadaki C, Stoupis G, Tsalikis L, Monastirioti A, Papadaki M, Maliotis N, Stratigos M, Mastrostamatis G, Mavroudis D, Agelaki S.

Oncotarget. 2019 Jan 29;10(9):966-981. doi: 10.18632/oncotarget.26629. eCollection 2019 Jan 29.

2.

Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.

Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S.

Mol Cancer Ther. 2019 Feb;18(2):437-447. doi: 10.1158/1535-7163.MCT-18-0584. Epub 2018 Nov 6.

PMID:
30401696
3.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

4.

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.

Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulias V.

Transl Oncol. 2017 Aug;10(4):693-698. doi: 10.1016/j.tranon.2017.06.005. Epub 2017 Jul 7.

Supplemental Content

Loading ...
Support Center